BACKGROUND: Diabetes mellitus carries a high risk for vascular events. Diabetics with different haptoglobin (Hp) types may carry different risk profiles, and may respond differently to vitamin E treatment. We aim to summarize the evidence about cardiovascular risk in diabetic patients, according to their Hp type, and the effect of vitamin E treatment on these sub-groups. METHODS: We searched MEDLINE and on-going trials' databases until February 2011; gray literature; reference lists of identified articles; and experts. Two investigators screened and selected studies that prospectively followed cardiovascular outcomes in diabetic patients with different Hp types (natural history analysis), and randomized controlled trials reporting the effect of vitamin E on cardiovascular outcomes in diabetics, in which Hp typing was performed (interventional analysis). RESULTS: Five and three studies, comprising 1829 and 2110 patients, were eligible for the natural history and the interventional analyses, respectively. The percentage of diabetic patients experiencing non-fatal MI, stroke, or cardiovascular death was significantly higher in the Hp 2-2 population (odds ratio (OR) 2.03 (95% confidence interval (CI) 1.46 to 2.81)). In patients with Hp 2-2 genotype, the OR for a combined endpoint was 0.66 in favor of the vitamin E treated group (95% CI 0.48 to 0.9). This effect was not shown in other Hp types. CONCLUSION: Hp type 2-2 carries a high risk of cardiovascular events in diabetic patients. A pharmacogenomic approach towards treatment of diabetic patients with vitamin E may be warranted.
BACKGROUND:Diabetes mellitus carries a high risk for vascular events. Diabetics with different haptoglobin (Hp) types may carry different risk profiles, and may respond differently to vitamin E treatment. We aim to summarize the evidence about cardiovascular risk in diabeticpatients, according to their Hp type, and the effect of vitamin E treatment on these sub-groups. METHODS: We searched MEDLINE and on-going trials' databases until February 2011; gray literature; reference lists of identified articles; and experts. Two investigators screened and selected studies that prospectively followed cardiovascular outcomes in diabeticpatients with different Hp types (natural history analysis), and randomized controlled trials reporting the effect of vitamin E on cardiovascular outcomes in diabetics, in which Hp typing was performed (interventional analysis). RESULTS: Five and three studies, comprising 1829 and 2110 patients, were eligible for the natural history and the interventional analyses, respectively. The percentage of diabeticpatients experiencing non-fatal MI, stroke, or cardiovascular death was significantly higher in the Hp 2-2 population (odds ratio (OR) 2.03 (95% confidence interval (CI) 1.46 to 2.81)). In patients with Hp 2-2 genotype, the OR for a combined endpoint was 0.66 in favor of the vitamin E treated group (95% CI 0.48 to 0.9). This effect was not shown in other Hp types. CONCLUSION: Hp type 2-2 carries a high risk of cardiovascular events in diabeticpatients. A pharmacogenomic approach towards treatment of diabeticpatients with vitamin E may be warranted.
Authors: Andrew P Levy; Hertzel C Gerstein; Rachel Miller-Lotan; Robert Ratner; Matthew McQueen; Eva Lonn; Janice Pogue Journal: Diabetes Care Date: 2004-11 Impact factor: 19.112
Authors: Andrew P Levy; Irit Hochberg; Kathleen Jablonski; Helaine E Resnick; Elisa T Lee; Lyle Best; Barbara V Howard Journal: J Am Coll Cardiol Date: 2002-12-04 Impact factor: 24.094
Authors: J P Boyle; A A Honeycutt; K M Narayan; T J Hoerger; L S Geiss; H Chen; T J Thompson Journal: Diabetes Care Date: 2001-11 Impact factor: 19.112
Authors: Ariel Roguin; Werner Koch; Adnan Kastrati; Doron Aronson; Albert Schomig; Andrew P Levy Journal: Diabetes Care Date: 2003-09 Impact factor: 19.112
Authors: K M Venkat Narayan; James P Boyle; Theodore J Thompson; Stephen W Sorensen; David F Williamson Journal: JAMA Date: 2003-10-08 Impact factor: 56.272
Authors: Nina S Levy; Moshe Vardi; Shany Blum; Rachel Miller-Lotan; Yefim Afinbinder; Patricia A Cleary; Andrew D Paterson; Bhupinder Bharaj; Janet K Snell-Bergeon; Marian J Rewers; Orit Lache; Andrew P Levy Journal: Clin Chem Lab Med Date: 2013-08 Impact factor: 3.694
Authors: Alessandra Saldanha de Mattos Matheus; Lucianne Righeti Monteiro Tannus; Roberta Arnoldi Cobas; Catia C Sousa Palma; Carlos Antonio Negrato; Marilia de Brito Gomes Journal: Int J Hypertens Date: 2013-03-04 Impact factor: 2.420
Authors: Michael I McBurney; Elaine A Yu; Eric D Ciappio; Julia K Bird; Manfred Eggersdorfer; Saurabh Mehta Journal: PLoS One Date: 2015-08-19 Impact factor: 3.240